SRC and central nervous system cancer: Although no effects were found in PTEN expression in vitro (Supplementary Figure 3C) and in vivo (Supplementary Figure 4A, B), the activity of Src (Y416 Src) was reduced by TAT-Cx43266–283 in vivo (Supplementary Figure 4C), indicating that TAT-Cx43266–283 reduced the activity of the Src–FAK axis with the subsequent effects in glioma cell invasion in vivo.